Vanguard Group
ARGS

Vanguard Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Vanguard Group’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-52,269
Closed -$157K – 4159
2017
Q4 		$157K Buy
52,269
+9,707
+23% +$32.6K ﹤0.01% 3962
2017
Q3 		$152K Buy
42,562
+3,560
+9% +$17.1K ﹤0.01% 3953
2017
Q2 		$284K Sell
39,002
-3,354
-8% -$28.6K ﹤0.01% 3837
2017
Q1 		$382K Buy
42,356
+3,239
+8% +$205K ﹤0.01% 3803
2016
Q4 		$3.83M Buy
39,117
+2,348
+6% +$220K ﹤0.01% 3151
2016
Q3 		$3.65M Buy
36,769
+17,894
+95% +$1.87M ﹤0.01% 3148
2016
Q2 		$2.31M Buy
18,875
+6,870
+57% +$917K ﹤0.01% 3332
2016
Q1 		$1.54M Buy
12,005
+3,777
+46% +$305K ﹤0.01% 3464
2015
Q4 		$380K Buy
8,228
+370
+5% +$31.3K ﹤0.01% 3895
2015
Q3 		$762K Buy
7,858
+384
+5% +$45.5K ﹤0.01% 3719
2015
Q2 		$1.02M Buy
7,474
+314
+4% +$50.2K ﹤0.01% 3659
2015
Q1 		$1.28M Buy
7,160
+868
+14% +$151K ﹤0.01% 3565
2014
Q4 		$1.26M Buy
6,292
+50
+0.8% +$8.99K ﹤0.01% 3450
2014
Q3 		$1.26M Buy
6,242
+970
+18% +$152K ﹤0.01% 3443
2014
Q2 		$847K Sell
5,272
-348
-6% -$57.5K ﹤0.01% 3527
2014
Q1 		$1.12M Buy
+5,620
New +$1.12M ﹤0.01% 3417

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Vanguard Group's ARGS Position: Q1 2018 in Review

Vanguard Group sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 52,269 shares — an estimated $157K sold.

Vanguard Group first reported a position in ARGS in Q1 2014 and held it in 16 quarters. The position peaked at $3.83M in Q4 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Vanguard Group reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vanguard Group sold 52,269 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $157K.
  • Vanguard Group first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 16 quarters.
  • Vanguard Group's Argos Therapeutics, Inc. position peaked at $3.83M in Q4 2016.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.